Aastrom Biosciences ends drug trial, to cut half its workforce
March 27 (Reuters) - Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia - a form of peripheral arterial disease - and cut about half of its workforce.
The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently.
The company has about 71 employees, according to Thomson Reuters data.
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Four dead in apparent Connecticut murder-suicide
- South Korea expands air defense zone to partially overlap China's |
- Singer Susan Boyle reveals she has Asperger's syndrome: paper
- Winter storm pushes up U.S. East Coast after deep-freeze in the South